{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:34:27Z","timestamp":1791434067882,"version":"4.3.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The GM2 gangliosidoses (GM2), Tay-Sachs and Sandhoff diseases, are rare, autosomal recessive genetic disorders caused by mutations in the lysosomal enzyme \u03b2-hexosaminidase A <jats:italic>(HEXA)<\/jats:italic> or \u03b2-hexosaminidase B <jats:italic>(HEXB)<\/jats:italic> genes, respectively. A minority of patients have a late-onset form of disease that presents from late-childhood to adulthood and has a slowly progressive course with prolonged survival.<\/jats:p>\n<jats:p>Little research has been published documenting patient experiences with late-onset Tay-Sachs and Sandhoff diseases and how the disease impacts their daily lives and functioning. This study explored the most frequent symptoms and functional impacts experienced by patients with late-onset GM2 gangliosidosis through interviews with patients and caregivers.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A qualitative research study design was employed, using three focus groups and 18 one-on-one interviews with patients who were recruited at the National Tay-Sachs and Allied Diseases Annual Family Conference. Transcripts were generated from the discussions, and patient quotes were analyzed using a content analysis approach. Concepts were aggregated into symptom and functional impacts, and the frequency of mention in the focus groups and individual interviews was calculated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Key findings<\/jats:title>\n<jats:p>Many of the frequently described symptoms [muscle weakness (<jats:italic>n<\/jats:italic>\u2009=\u200919, 95%), \u201cclumsy\u201d gait (<jats:italic>n<\/jats:italic>\u2009=\u200912, 60%), fatigue (<jats:italic>n<\/jats:italic>\u2009=\u200910, 50%)] and impacts [difficulty walking (n\u2009=\u200919, 95%), falling (<jats:italic>n<\/jats:italic>\u2009=\u200917, 85%), and climbing stairs (<jats:italic>n<\/jats:italic>\u2009=\u200916, 80%)] disclosed by patients and caregivers were similar to those previously reported in the literature. However, less frequently described symptoms such as gastrointestinal issues (<jats:italic>n<\/jats:italic>\u2009=\u20094, 20%) and coughing fits (<jats:italic>n<\/jats:italic>\u2009=\u20095, 25%) have been expanded upon. This study evaluated the immediate impact of these symptoms on the patients\u2019 lives to highlight the burden of these symptoms and the functional limitations on daily living activities, independence, and emotional well-being. The findings were used to develop a conceptual disease model that could serve as a foundation for patient-centered outcomes in clinical trials and provide insights to the medical community that may benefit patient care.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study contributes to the current understanding of symptoms associated with late-onset GM2 gangliosidosis, and further identifies the many consequences and impacts of the disease. These symptoms and impacts could be measured in clinical trials to examine the effects of novel treatments from the patient perspective.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01354-3","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T18:03:51Z","timestamp":1586973831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases"],"prefix":"10.1186","volume":"15","author":[{"given":"Nicole","family":"Lyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Pulikottil-Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Rochmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krupnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Gwaltney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kissell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"1354_CR1","doi-asserted-by":"crossref","unstructured":"Mahuran DJ. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta. 1999;1455(2\u20133):105\u201338.","DOI":"10.1016\/S0925-4439(99)00074-5"},{"key":"1354_CR2","doi-asserted-by":"crossref","unstructured":"Bisel B, Pavone FS, Calamai M. GM1 and GM2 gangliosides: recent developments. Biomol Concepts. 2014;5(1):87\u201393.","DOI":"10.1515\/bmc-2013-0039"},{"key":"1354_CR3","volume-title":"GeneReviews","author":"MM Kaback","year":"2011","unstructured":"Kaback MM, Desnick RJ. Hexosaminidase A Deficiency. In: Adam M, Ardinger H, Pagon R, Wallace S, editors. GeneReviews. Seattle: University of Washington; 2011. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1218\/?report=reader#_NBK1218_pubdet_."},{"key":"1354_CR4","doi-asserted-by":"crossref","unstructured":"Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlation in 21 affected patients. Genet Med. 2005;7(2):119\u201323.","DOI":"10.1097\/01.GIM.0000154300.84107.75"},{"key":"1354_CR5","doi-asserted-by":"crossref","unstructured":"Sung AR, Moretti P, Shaibani A. Case of late-onset Sandhoff disease due to a novel mutation in the HEXB gene. Neurol Genet. 2018;4(4). https:\/\/ng.neurology.org\/content\/4\/4\/e260.","DOI":"10.1212\/NXG.0000000000000260"},{"key":"1354_CR6","doi-asserted-by":"crossref","unstructured":"Jahnov\u00e1 H, Poup\u011btov\u00e1 H, Jire\u010dkov\u00e1 J, Vl\u00e1\u0161kov\u00e1 H, Ko\u0161\u0165\u00e1lov\u00e1 E, Mazanec R, et al. Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay\u2013Sachs disease. J Neurol. 2019;266(8):1953\u20139.","DOI":"10.1007\/s00415-019-09364-3"},{"key":"1354_CR7","doi-asserted-by":"crossref","unstructured":"Malterud K. Qualitative research: standards, challenges, and guidelines. Lancet. 2001;358(9280):483\u20138.","DOI":"10.1016\/S0140-6736(01)05627-6"},{"key":"1354_CR8","doi-asserted-by":"crossref","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360.","DOI":"10.1177\/1049732315617444"},{"key":"1354_CR9","volume-title":"Patient and caregiver experience with late-onset Tay-Sachs and Sandhoff diseases. Patient Caregiv Exp with late-onset Tay-Sachs Sandhoff dis","author":"A Hamed","year":"2016","unstructured":"Hamed A, Krupnick RN, Kissell J, Kahn SR, Sathe S, Eichler F, et al. Patient and caregiver experience with late-onset Tay-Sachs and Sandhoff diseases. Patient Caregiv Exp with late-onset Tay-Sachs Sandhoff dis. San Diego: WORLDSymposium on Lysosomal Diseases; 2016."},{"key":"1354_CR10","unstructured":"Matalon R, Delgado L, Young B, Matalon D, Schiffmann R. GM2 Gangliosidoses. Neurol Medlin. 1994. Available from: http:\/\/www.medlink.com\/article\/gm2_gangliosidoses."},{"key":"1354_CR11","first-page":"1023","volume":"15","author":"B Packer-Muti","year":"2010","unstructured":"Packer-Muti B. Conducting a focus group. Qual Rep. 2010;15:1023\u20136 Available from: https:\/\/nsuworks.nova.edu\/tqr\/vol15\/iss4\/20\/.","journal-title":"Qual Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01354-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01354-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01354-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:14:45Z","timestamp":1618445685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01354-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01354-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"6 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval for this study was granted by Schulman IRB and Advarra IRB. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of the study results was obtained from patients and caregivers. De-identified information is presented to ensure anonymity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NL, RPJ, CR, JK, TF, and AH are employees of Sanofi Genzyme. RK and NS were employees of IQVIA, Inc. at the time the study was conducted and were paid consultants of Sanofi Genzyme. CG is an employee of Gwaltney Consulting and was a paid consultant of Sanofi Genzyme. GFC is an employee of Gerald Cox Rare Care Consulting, LLC and was an employee of Sanofi Genzyme at the time this study was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}